Hylase: Hyaluronidase for Dissolving Filler and Its Limits

After lip or under-eye filler, you are unhappy with the shape or have swelling, and someone suggests an injection of “Hylase.” Is it a special dissolving product, how fast does it work, and will you look exactly as before? Hylase commonly refers to a medicine containing the enzyme hyaluronidase. But German Hylase and British Hyalase, with an additional “a,” are distinct nationally marketed products, not a laser, a device or a universal remover of any filler. Hyaluronidase breaks down hyaluronic acid (HA), so clinicians use it in some aesthetic-filler complications and unwanted outcomes involving HA products.

The exact label matters. In the UK, Hyalase 1500 I.U. is a prescription hyaluronidase powder for solution for injection or infusion, with Wockhardt UK Ltd listed in the British medicines register. German Hylase “Dessau” is a distinct product in 150 and 300 I.E. strengths. Older directories still name Esteve Pharmaceuticals GmbH, but the new holder and industry coverage report that rights passed to Kadima Med GmbH in May 2026. In a statement dated 21 October 2026, the company said an interim supply solution was ready for dispatch, but dispatch still depended on a formal review by the Rhineland-Palatinate health ministry. That is a statement by the rights holder, not independent confirmation of pharmacy stock or availability in Armenia. Registration countries, strengths, instructions and supply histories differ. “Hylase” may also be used loosely to describe any hyaluronidase enzyme. Before deciding, check the actual pack, current authorisation holder, product leaflet, batch, expiry date and lawful supply in the country of treatment.

What is an officially indicated use, and what belongs to aesthetic practice?

The British Hyalase 1500 I.U. product information describes helping subcutaneous or intramuscular injections, local anaesthetics and subcutaneous infusions disperse and absorb, and promoting resorption of excess fluid and blood in tissue. Dissolving cosmetic filler is not among its listed authorized indications. In the UK, using it for that purpose is off-label: outside the approved product information. That does not prove it is ineffective; it does require clinical justification, a risk assessment and informed consent.

Clinical guidance from CMAC discusses hyaluronidase for certain HA-filler complications, including suspected vascular occlusion, when a vessel's blood supply is obstructed. This guidance concerns clinical use of an enzyme class, not identical approved indications for every brand. UK registration does not establish the status of a German pack in Armenia, and German labeling does not prove supplies in Yerevan. Local legality, actual availability and prices require independent checks. For Hylase “Dessau,” it is particularly important to verify the current product information after the change of authorization holder.

If you dislike the filler result, first establish what happened

“My lips look too big a few hours after injection” is not the same as “hard lumps appeared months later.” Early swelling can account for some extra fullness, so immediate dissolution may not be justified. Later lumps may reflect an inflammatory response, infection, filler accumulation, scarring or other causes; appearance alone does not determine treatment. If the substance is unknown, request records showing the filler name, date, volume, site and, ideally, batch number.

Persistent puffiness under the lower eyelid is another distinct problem. Misplaced HA is only one possibility; drainage of tissue fluid and individual anatomy also matter. An enzyme cannot correct every source of swelling. In difficult cases the clinician may use soft-tissue ultrasound to locate a deposit or identify other changes, but the need for imaging depends on examination. Acute warning signs must not wait for diagnostic imaging.

Sudden or worsening severe pain, blanching, an unusual mottled skin colour, cold skin or visual changes after a recent filler injection are not a matter of routine aesthetic reversal. Suspected vascular occlusion requires immediate medical assessment by a trained clinician. New visual disturbance or neurological symptoms call for emergency care, not a delayed cosmetic visit. Ordering an ampoule and injecting yourself is dangerous.

What can dissolving achieve, and what cannot be promised?

If the previously injected material really is HA and there is a clinical reason to use the enzyme, the aim is to reduce some or all of that HA. Results depend on how the HA is cross-linked, the amount, depth and distribution, how long it has been present and the body's tissue response. Some deposits dissolve unevenly; a clinician may consider another review or treatment. A dose mentioned in somebody else's video cannot guarantee the same outcome for you.

A complete aesthetic reversal is not guaranteed. Even if HA is reduced, its original placement, tissue stretching, inflammation or age-related changes may mean your face will not exactly match your older pictures. The enzyme can temporarily affect natural HA in tissue, too, so the immediate appearance may seem unfamiliar. No honest clinician can promise millimetre-perfect restoration or an effect restricted to an ideally defined point.

PLLA, calcium hydroxylapatite, polymethylmethacrylate and silicone fillers are not dissolved by hyaluronidase in the same way as HA products. Guessing about an unknown material can increase irritation or delay necessary care. Comparing hyaluronidase brands calls for checking their separate instructions; information about Liporase cannot automatically be applied to Hylase.

What is the appointment like, and what might be visible afterward?

For an elective decision, the clinician asks about earlier fillers, when the change began, allergies, conditions, medicine, pregnancy and breastfeeding. They examine and sometimes palpate the area. If treatment is justified, you should discuss the specific enzyme preparation, local pain relief, expected discomfort and follow-up. Injections may sting, burn slightly or feel like pressure; other people's reviews cannot predict your experience.

Needle marks, swelling, tenderness, redness or bruising may follow immediately. A reduction in volume can sometimes appear quickly, but tissue reactions distort the early view. Do not book a close-up shoot or a high-stakes meeting the same day expecting no visible traces. In the days that follow a clinician may judge the remaining issue more reliably. Follow-up timing depends on the reason for treatment and the course of recovery, not a universal promotional timetable.

Do not apply unknown remedies, vigorously massage the site or try additional enzyme injections yourself. The treating clinician should explain restrictions on makeup, exercise, heat and pressure. They must also tell you how to reach them if pain or swelling escalates. Returning to work and having no visible bruise are two different things: a minor injection can still show at close range.

Allergies, contraindications and why a test does not guarantee safety

The UK Hyalase information contraindicates use in known hypersensitivity to hyaluronidase. It also says the product must not be injected intravenously, used at a site of infection or malignancy, or used to reduce swelling from bites or stings. In pregnancy it advises avoidance if a safer alternative exists; during breastfeeding it calls for caution. Discuss postponing an optional, purely aesthetic dissolution. These UK statements must not automatically be applied to German Hylase “Dessau”. The separate current German labels for 150 and 300 I.E. describe ophthalmic use alongside local anaesthesia and contraindicate use with allergy to hyaluronidase or bovine proteins, during breastfeeding and from the third trimester of pregnancy. They also list congenital heart defects, venous congestion, shock, infection and cancer among contraindications; during the first and second trimesters an individual risk–benefit assessment is required. This is not the complete contraindication list, and neither label establishes cosmetic filler dissolution as an approved indication. Before consenting, read the current information for the specific proposed product and discuss it with the clinician.

The British information describes local reactions and rare severe allergic reactions including anaphylaxis. The practitioner must be equipped and trained to respond. CMAC stresses a careful allergy history; elective cases may require individual decisions on allergy referral or investigation. Yet a skin test is no absolute assurance of safety, and suspected vascular occlusion should not be left untreated while waiting for a test. The fuller questions are addressed separately in hyaluronidase allergy and hyaluronidase skin testing.

Mention any earlier reaction to the enzyme or severe allergy, and all medication you take: compatibility with co-administered drugs needs medical review. The possibility of allergy should affect how necessary the procedure is judged to be. “It is a natural enzyme, therefore harmless” is false; biological activity does not rule out a serious reaction.

How to evaluate an offer to “dissolve filler with Hylase”

• Ask to see the precise pack and corresponding instructions. Check active ingredient, potency, manufacturer, storage conditions and registration in the treatment country.
• Which exact earlier filler will be treated, and how do we know it contains HA? If documentation is missing, discuss records or appropriate diagnostic assessment.
• Is the aim to reduce excess cosmetic volume, investigate inflammation or treat a potentially urgent complication? These require different plans and timings.
• Why was this product selected? What clinical evidence supports any off-label use, what limits apply and what happens if the effect is incomplete?
• Review allergy history, emergency equipment, follow-up arrangements, written instructions and possible additional review costs.
• Ask about alternatives: waiting for swelling to settle, treating another established cause, referral to dermatology or surgery, or making no intervention.

Walk away from anyone who hides the active ingredient, claims every filler dissolves with one injection, offers home administration or says a “little test drop” eliminates allergy risk. A confirmed urgent problem needs medical care; with a stable aesthetic concern you have time to choose. Wanting your familiar facial expression back is understandable, but a safer decision begins with identifying the cause and discussing what is, and is not, reversible.